Preventing recurrence and progression in superficial bladder cancer

摘要

One of the most important recent developments in the management of superficial bladder cancer has been the unequivocal demonstration that intravesical immunotherapy can prevent progression of the disease to muscle-invasive cancer, whereas intravesical chemotherapy apparently cannot. Toxicity for these two forms of therapy still remains a major problem and attempts at reducing the dosage of immunotherapeutic agents are underway. The promise that various simple natural agents, taken by mouth, can have a significant effect on bladder cancer prophylaxis is being energetically explored at the present time.